ライフサイエンスコーパス: pyrexia

1 at least one adverse event (most common was pyrexia).

2 oute responded with primary and/or secondary pyrexia.

3 with typical signs including tachycardia and pyrexia.

4 evels), leading to an increased incidence of pyrexia.

5 n with a sore throat, headache, myalgia, and pyrexia.

6 vents assessed as related to KGF were due to pyrexia.

7 s (AEs) with T-VEC were fatigue, chills, and pyrexia.

8 monia, febrile neutropenia, dehydration, and pyrexia.

9 pain, generalized weakness, weight loss, and pyrexia.

10 t a rate >=2 times that of placebo) included pyrexia (105 [12%] of 870 for 300 mg rocatinlimab and 26

11 e dabrafenib only group; the most common was pyrexia (108 patients, 52%) in the dabrafenib and tramet

12 t were cytokine release syndrome (41 [28%]), pyrexia (11 [8%]), pneumonia (nine [6%]), and infusion-r

13 ma (20 patients, 11%), fatigue (14, 8%), and pyrexia (11, 6%).

14 of 231 patients), diarrhoea (116 [50%]), and pyrexia (115 [50%]).

15 events were pneumonia (29 [12%] vs 11 [4%]), pyrexia (12 [5%] vs 10 [4%]), and COVID-19 (11 [5%] vs 1

16 nine [12%]), nausea (16 [11%] vs 13 [18%]), pyrexia (13 [9%] vs nine [12%]), and decreased appetite

17 tment-emergent adverse events, most commonly pyrexia (16 [12%]).

18 ts were reported, with the most common being pyrexia (16 [16%] of 101 events) and orofacial dyskinesi

19 of 75), decreased appetite (18 [24%] of 75), pyrexia (16 [21%] of 75), and decreased activity (15 [20

20 %]), convulsion (18 [23%] vs ten [26%]), and pyrexia (17 [22%] vs six [15%]).

21 cough (38 [63%] of 60), vomiting (17 [28%]), pyrexia (17 [28%]), and rhinorrhoea (15 [25%]).

22 most frequently reported adverse events were pyrexia (18%), hypokalemia (15%), and hypophosphatemia (

23 mmon signs and symptoms for all reports were pyrexia (19%), rash (17%), pain (13%), and arthralgia (1

24 ycemia (2%; one of 64 patients), and grade 1 pyrexia (2%, one of 64 patients).

25 higher were anaemia (27 [49%] patients) and pyrexia (20 [36%] patients).

26 fatigue (36/3), nausea (25/3), rash (25/3), pyrexia (20/3), and chills (20/0).

27 ilure (25 [10%]; five related to treatment), pyrexia (21 [8%]; three related to treatment), bacteraem

28 vomiting (24% of patients), cough (21%), and pyrexia (21%).

29 6%) had anaemia, 23 (36%) versus seven (21%) pyrexia, 22 (34%) versus six (18%) decreased appetite, 1

30 rade 3/4, 18%), followed by infection (32%), pyrexia (23%), neutropenia (23%), headache (18%), and na

31 arthralgia (33%), hyperkeratosis (27%), and pyrexia (24%).

32 ue (35%, 52/148), diarrhea (32%, 47/148) and pyrexia (24%, 36/148), with no grade 5 TRAEs reported an

33 The most common adverse events were pyrexia (27 [42%] vs 11 [32%]), nausea (20 [31%] vs 7 [2

34 rade >/=3%) diarrhea (40/18), nausea (33/5), pyrexia (28/0), fatigue (25/3), rash (23/3), decreased a

35 s) with BEMPEG plus NIVO versus TKI included pyrexia (32.6% v 2.0%) and pruritus (31.3% v 8.8%).

36 and more common than the placebo group) were pyrexia (36 [17%] patients), nasopharyngitis (30 [14%] p

37 (n=87), the most common adverse events were pyrexia (36 [41%] patients) and fatigue (31 [36%]).

38 0.7/4/20 mg step-up], neutropenia (39%), and pyrexia (38%).

39 , both groups), arthralgia (39.1% vs 28.1%), pyrexia (38.7% vs 26.0%), alanine aminotransferase incre

40 anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4 [2%]), and pneumonia (4 [2%]) with pacritinib

41 ients) treatment-related adverse events were pyrexia (40.8%), fatigue (25.7%), chills (25.7%), nausea

42 rrhea (including colitis) (64%), rash (58%), pyrexia (42%), nausea (38%), chills (36%), cough (33%),

43 Nausea (51.5%), fatigue (51.5%), pyrexia (42.4%), and dyspnea and thrombocytopenia (each

44 ents with stepwise dosing were tremor (48%), pyrexia (44%), fatigue (26%), and edema (26%).

45 safety analyses: common adverse events were pyrexia (47 patients [69%]), primarily associated with c

46 % (1,490/7,154) of patients, most frequently pyrexia (5.1% [366/7,154]) and vomiting (4.2% [303/7,154

47 Cough, fatigue, and pyrexia (52% each), nausea and peripheral sensory neurop

48 The most frequent AEs were pyrexia (58%), febrile neutropenia (40%), and headache (

49 common treatment-related adverse events were pyrexia (58.2%), chills (47.3%), and hyperglycemia (40.0

50 rse events (TRAEs) (any grade, grade 3) were pyrexia (63.0%, 3.7%, respectively) and abdominal pain (

51 hea (12%), pruritus (12%), fatigue (7%), and pyrexia (7%).

52 positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%).

53 de in the tebentafusp group were rash (83%), pyrexia (76%), pruritus (70%), and hypotension (38%).

54 ment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common.

55 dverse events regardless of attribution were pyrexia (91%), rash (83%), pruritus (83%), nausea (74%),

56 In a model of yeast induced pyrexia, administration of APAP evoked a marked hypother

57 The frequency of pyrexia after vaccine or placebo was higher in children

58 blood-milk permeability barrier followed by pyrexia and a pronounced leukocytic influx.

59 y episodes of E. coli urinary sepsis causing pyrexia and a raised creatinine level.

60 th the most common (>/=5% of patients) being pyrexia and autoimmune haemolytic anaemia (seven [7%] ea

61 Most events of pyrexia and chills were considered injection-related rea

62 ated with self-limiting grade 1-2 headaches, pyrexia and fatigue that diminish with each vaccination.

63 Two treatment-related deaths (of pyrexia and infection) occurred in the tiragolumab plus

64 vents that were possibly study-drug related: pyrexia and intraocular inflammation that resolved with

65 (33.3%), upper respiratory tract infection, pyrexia, and diarrhea (26.7% each) were the most common

66 had decreased appetite, three (9%) of 33 had pyrexia, and five (15%) of 33 had decreased activity.

67 response that led to systemic inflammation, pyrexia, and hallmark symptoms of clinical malaria acros

68 ion site reactions, influenza-like symptoms, pyrexia, and headache.

69 on AEs in >or= 20% of patients were fatigue, pyrexia, and headache; most were grade 1 or 2.

70 on adverse events with IGIV-C were headache, pyrexia, and hypertension.

71 ommon adverse events were headache, fatigue, pyrexia, and influenza-like illness at 12 weeks (95 [37%

72 ab vs. placebo included headache, sinusitis, pyrexia, and influenza.

73 ab vs. placebo included headache, sinusitis, pyrexia, and influenza.

74 receptor potential (TRP) channels dTRPA1 and Pyrexia, and is also timed by the clock.

75 logic adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue,

76 mon grade 1 to 2 toxicities were stomatitis, pyrexia, and nausea, whereas grade 3 and 4 toxicities we

77 accelerated decline in parasite density and pyrexia, and no DPC.

78 Grade 1-2 diarrhoea, arthralgia, pyrexia, and rash were increased with atezolizumab.

79 influenza B infection), one life-threatening pyrexia, and ten events that led to hospital admission.

80 Somnolence, pyrexia, and upper respiratory tract infections occurred

81 Headache, pyrexia, and vomiting were the most common adverse event

82 ugh, infective pulmonary exacerbation of CF, pyrexia, and vomiting.

83 most frequently reported adverse events were pyrexia (apitegromab, 33 [26%] of 128 vs placebo, 17 [28

84 facial diplegia, injection-site erythema and pyrexia, autoimmune hemolytic anemia, and suspected lack

85 Itacitinib was well tolerated, with pyrexia being the most common treatment-emergent adverse

86 ed, two cases of sepsis and one case each of pyrexia, cardiogenic pulmonary edema and pulmonary embol

87 The most common adverse events were fatigue, pyrexia, diarrhea, nausea, neutropenia, and peripheral n

88 Serious TRAEs included one count each of pyrexia, duodenitis, increased transaminases and hyperth

89 ea (16 [25%], 11 [16%], and nine [13%]), and pyrexia (eight [13%], 14 [20%], and one [1%]).

90 verse events, the most frequent of which was pyrexia (eight [19%]).

91 The most common adverse events were pyrexia (eight [73%] of 11 patients), upper respiratory

92 related adverse events (TRAEs) >10% included pyrexia, fatigue, musculoskeletal and injection site pai

93 therapy, 23 (85%) of which were infectious (pyrexia [five events in three patients], device-related

94 This may account for anecdotal reports of pyrexia following treatment and may be significant in te

95 verse events related to study treatment were pyrexia for dabrafenib (eight [6%] of 125 patients) and

96 s of an epigastric swelling and undocumented pyrexia for four months was referred for sonographic eva

97 coded term for non-serious events (29%), and pyrexia for non-fatal serious events (38%).

98 oid arthritis for the treatment subgroup and pyrexia for the prevention subgroup.

99 o patients) grade 3 or 4 adverse events were pyrexia (four [11%]), alanine aminotransferase increase

100 nine aminotransferase increase (five [14%]), pyrexia (four [11%]), aspartate aminotransferase increas

101 mon in the placebo plus erlotinib group were pyrexia (four [2%]) and pneumothorax (three [1%]).

102 regardless of study drug relationship, were pyrexia (four [3%] of 125) and headache (three [2%]).

103 atment-related adverse events, most commonly pyrexia (four [3%]), and hypertension and pleural effusi

104 igator), pneumonia (four [7%] patients), and pyrexia (four [7%] patients).

105 The most frequent AE during treatment was pyrexia (grade 1 or 2, 75%; grade 3, 6%).

106 , disrupting negative geotaxis (painless and pyrexia), hearing (nompC), or both (nanchung and inactiv

107 at least 5% of patients in either group were pyrexia, hypokalaemia, pneumonia, septic shock, and anae

108 Endpoints were postoperative pyrexia, ileus, wound infection, intra-abdominal abscess

109 rted in 32 (56%) of 57 patients and included pyrexia in nine (16%), anaemia in three (5%), confusiona

110 up, including headache (in 42% of patients), pyrexia (in 19%), and nausea (in 16%).

111 adverse events included cough, headache, and pyrexia; in most of the children who had adverse events,

112 SBRT were abdominal pain, acute cholangitis, pyrexia, increased blood lactic acid, and increased lipa

113 being elevation of liver function tests and pyrexia, most of which resolved with drug interruption o

114 most common adverse events were headache and pyrexia, mostly mild, and reported in 20% and 13% of the

115 s in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain.

116 AEs included cardiac AEs (n = 3, 4 events), pyrexia (n = 1, 2 events), and dyspnea (n = 1, 2 events)

117 frequently nasopharyngitis (n = 15, 55.6%), pyrexia (n = 14, 51.9%) and vomiting (n = 13, 48.1%).

118 (n = 6, 22.2%), headache (n = 4, 14.8%) and pyrexia (n = 3, 11.1%).

119 (>2 patients) were diarrhea/colitis (n = 9), pyrexia (n = 4), hypotension (n = 3), and sepsis (n = 3)

120 8 patients (75%); only rash (n = 5; 21%) and pyrexia (n = 4; 17%) and occurred in >/= 10% of patients

121 , nausea (n = 10), thrombocytopenia (n = 9), pyrexia (n = 9), decreased appetite (n = 8), fatigue (n

122 hypersensitivity (n=1), panic attack (n=1), pyrexia (n=1), and COVID-19 (n=1).

123 t adverse events in the olesoxime group were pyrexia (n=34), cough (n=32), nasopharyngitis (n=25), an

124 infection (n=7 [7%]), pneumonia (n=7 [7%]), pyrexia (n=4 [4%]), cellulitis (n=3 [3%]), fall (n=3 [3%

125 The most common serious adverse events were pyrexia (n=9), pneumonia (n=6), and sepsis (n=6).

126 In the double-blind phase, headache, pyrexia, nasopharyngitis, sleep disorder, and tremor wer

127 e some features of Chagas's disease, such as pyrexia, neuroprotection, and fibrosis, and might result

128 e dabrafenib-only group (2% vs. 9%), whereas pyrexia occurred in more patients (51% vs. 28%) and was

129 ical suspicion of GvHD (skin rash, diarrhea, pyrexia, pancytopenia, or anemia, without an obvious alt

130 ions (>=5%) were hearing loss, otitis media, pyrexia, pneumonia, and diarrhea.

131 puts via Drosophila TRPA channels, TRPA1 and Pyrexia (Pyx).

132 bone pain, diarrhoea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomi

133 ment center with minor illnesses and without pyrexia served as controls.

134 dverse events were pneumonia (nine [6%]) and pyrexia (seven [5%]) in the pembrolizumab plus lenalidom

135 t frequent were abdominal pain (seven [5%]), pyrexia (seven [5%]), cholangitis (five [3%]), and pleur

136 This might explain the observed link between pyrexia, severe stroke and poor outcome.

137 ly to explain the relationship between early pyrexia, severe stroke and poor outcome.

138 The most common serious adverse events were pyrexia (six [12%]), febrile neutropenia (five [10%]), l

139 The most common serious adverse event was pyrexia (six [20%] of 30; one in B2, three in C1, two in

140 31 [27%]), febrile neutropenia (seven [6%]), pyrexia (six [5%]), pancytopenia (three [3%]), and pneum

141 release syndrome (21 [24%] of 88 patients), pyrexia (six [7%] of 88 patients), immune effector cell-

142 Pyrexia (six patients [2%]) and dehydration (five patien

143 group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal results on liver-funct

144 common serious adverse event (any grade) was pyrexia (three [4%] patients).

145 mon serious adverse events were: in group A, pyrexia (three [4%]), diarrhoea (two [3%]), urinary trac

146 shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group.

147 sorimotor neuropathy (two [2%] patients) and pyrexia (two [2%]).

148 inical features (purulent vaginal discharge, pyrexia, uterine tenderness, and leukocytosis) or by the

149 subpopulations of neurons, and the TRPA gene pyrexia was expressed in cap cells that may interact wit

150 The rate of pyrexia was increased with combination therapy, whereas

151 19% receiving monotherapy (P=0.09), whereas pyrexia was more common in the combination 150/2 group t

152 Pyrexia was the most common adverse event (ten [11%] eve

153 e categories of infections and infestations; pyrexia was the only serious adverse event reported in m

154 occurred in the first 6 months, and 1 event (pyrexia) was identified as being vaccine-related; the pa

155 veloping any grade >/=2 influenza symptom or pyrexia, was not achieved, TCN-032-treated subjects show

156 orted serious adverse events; haemolysis and pyrexia were the most common (each occurring in two [5%]

157 Injection site reactions, chills, and pyrexia were the most common AEs.

158 eatment-related serious AEs (hypotension and pyrexia) were reported in 1 participant within 6 hours o

159 ncluding febrile neutropenia, pneumonia, and pyrexia, were more common in the idelalisib group (140 [